Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease myelodysplastic syndrome
Symptom C0282193|iron overload
Sentences 19
PubMedID- 20332502 iron overload in myelodysplastic syndromes.
PubMedID- 23937987 A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
PubMedID- 26453076 Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents.
PubMedID- 22829233 Clearly elevated cardiac r2* was found in two myelodysplastic syndrome (mds) patients with severe liver iron overload.
PubMedID- 22338168 Pay great attention to the diagnosis and treatment of iron overload in myelodysplastic syndromes.
PubMedID- 25348770 Deferasirox for managing iron overload in people with myelodysplastic syndrome.
PubMedID- 26224043 Background: hepatic iron overload is common in patients with myelodysplastic syndromes undergoing hematopoietic cell transplantation (hct) and may predispose to peri- and post-hct toxicity.
PubMedID- 25764148 Deferasirox (dfx) is an orally administered iron chelator approved for use in patients with transfusion-dependent iron overload due to myelodysplastic syndromes (mds).
PubMedID- 19903678 Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a gitmo study.
PubMedID- 23628060 Current understanding of iron overload hazard in patients with myelodysplastic syndrome.
PubMedID- 23086508 Transfusion therapy in the treatment of patients with blood disorders such as β-thalassemia major, sickle cell disease (scd), and myelodysplastic syndromes (mds) rapidly leads to iron overload and subsequent tissue and organ damage unless effective chelation therapy is used to control tissue iron levels .
PubMedID- 22924125 Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial.
PubMedID- 19719471 Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
PubMedID- 20125080 iron overload in myelodysplastic syndromes: diagnosis and management.
PubMedID- 26576280 iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy.
PubMedID- 21069694 Deferasirox for managing iron overload in people with myelodysplastic syndrome.
PubMedID- 23766520 Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes.
PubMedID- 25516455 Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
PubMedID- 25743685 Overall, about 760 myelodysplastic syndrome (mds) patients with iron overload receiving deferasirox were included in six different studies, and an increase in hemoglobin level was reported to range from 6 to 44.5%, an increase in platelet count from 13 to 61%, and in neutrophil count from 3 to 76%.

Page: 1